46
Participants
Start Date
May 21, 2020
Primary Completion Date
June 30, 2025
Study Completion Date
December 31, 2025
Cabozantinib
Cabozantinib 40 mg orally daily for 3 cycles
Atezolizumab
Atezolizumab 1200 mg IV every 3 weeks for 3 cycles
Cystectomy
Patients will receive three cycles of treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw consent.
University of Rochester Medical Center, Rochester
Virginia Commonwealth University, Richmond
Vanderbilt-Ingram Cancer Center, Nashville
Froedtert and The Medical College of Wisconsin, Milwaukee
Washington University School of Medicine, St Louis
John Theurer Cancer Center, Hackensack
Collaborators (2)
Exelixis
INDUSTRY
Genentech, Inc.
INDUSTRY
Medical College of Wisconsin
OTHER
Deepak Kilari
OTHER